AGG-523

Overview

AGG-523 (PF-5212371) is an orally active, reversible, non-hydroxamate, zinc-binding selective inhibitor of ADAMTS4 and ADAMTS5 with IC 50 of <0.03 and 0.04 μM. AGG-523 also inhibits MMP -2, -8, 12 activity AGG-523 attenuates release of aggrecanase-generated ARG-aggrecan fragments into synovial fluid, reduces surgery-induced ARG-aggrecan release in rat joint models, and inhibits aggrecanase activity to slow cartilage degradation. AGG-523 can be used for the research of osteoarthritis.

Application

Products | Products > Disease Areas > Musculoskeletal and Skin Disease | Products > Disease Areas > Inflammation or Immune System Disease | Products > Disease Areas > Arthritis | Products > Disease Areas > Osteoarthritis | Products > Signaling Pathways > Metabolic Enzyme/Protease | Products > Research Areas > Inflammation/Immunology | Products > Signaling Pathways > ADAMTS | Products > Signaling Pathways > MMP

Product Information

• Catalog No.: HY-160822
• CAS No.: 920289-29-8
• Molecular Formula: C28H29FN2O4
• Molecular Weight: 476.54
• Purity: 99.32%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
• Solubility: ≥ 5 mg/mL (10.49 mM); Clear solution
• Availability: In-stock

Source

Original product source